Literature DB >> 28025704

Pulmonary vascular remodeling in pulmonary hypertension.

Rubin M Tuder1.   

Abstract

Pulmonary vascular remodeling is the key structural alteration in pulmonary hypertension and involves changes in the intima, media and adventitia, often with the interplay of inflammatory cells. This review examines the pathology of these changes and highlights some of the pathogenetic mechanisms that underlie the remodeling process.

Entities:  

Keywords:  Endothelial cells; Lung; Pulmonary hypertension; Pulmonary remodeling; Smooth muscle cells

Mesh：

Year:  2016        PMID： 28025704      PMCID： PMC5408737          DOI： 10.1007/s00441-016-2539-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN： 0302-766X            Impact factor:   5.249


  39 in total

1.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Architecture of the human lung. Use of quantitative methods establishes fundamental relations between size and number of lung structures.

Authors:  E R WEIBEL; D M GOMEZ
Journal:  Science       Date:  1962-08-24       Impact factor: 47.728

3.  Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1.

Authors:  Neil J Davie; Evgenia V Gerasimovskaya; Stephen E Hofmeister; Aaron P Richman; Peter L Jones; John T Reeves; Kurt R Stenmark
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 4.  Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract.

Authors:  Christian Mühlfeld; Matthias Ochs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-05-24       Impact factor: 5.464

Review 5.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Elvira Stacher; Jeffrey Robinson; Rahul Kumar; Brian B Graham
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

6.  An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure.

Authors:  Connie C W Hsia; Dallas M Hyde; Matthias Ochs; Ewald R Weibel
Journal:  Am J Respir Crit Care Med       Date:  2010-02-15       Impact factor: 21.405

Review 7.  How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.

Authors:  Rubin M Tuder
Journal:  Drug Discov Today       Date:  2014-05-29       Impact factor: 7.851

8.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

9.  Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.

Authors:  N F Voelkel; R M Tuder; J Bridges; W P Arend
Journal:  Am J Respir Cell Mol Biol       Date:  1994-12       Impact factor: 6.914

Review 10.  Mechanisms of disease: pulmonary arterial hypertension.

Authors:  Ralph T Schermuly; Hossein A Ghofrani; Martin R Wilkins; Friedrich Grimminger
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419
View more
  59 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  MicroRNA-mediated downregulation of K+ channels in pulmonary arterial hypertension.

Authors:  Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-25       Impact factor: 5.464

Review 3.  Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension.

Authors:  Brandon L Carman; Dan N Predescu; Roberto Machado; Sanda A Predescu
Journal:  Am J Pathol       Date:  2019-03-26       Impact factor: 4.307

4.  Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension.

Authors:  Morgan E Whitaker; Vineet Nair; Shripad Sinari; Parinita A Dherange; Balaji Natarajan; Lindsey Trutter; Evan L Brittain; Anna R Hemnes; Eric D Austin; Kumar Patel; Stephen M Black; Joe G N Garcia; Jason X Yuan Md PhD; Rebecca R Vanderpool; Franz Rischard; Ayako Makino; Edward J Bedrick; Ankit A Desai
Journal:  Am J Med       Date:  2018-02-05       Impact factor: 4.965

Review 5.  Perspective: pathobiological paradigms in pulmonary hypertension, time for reappraisal.

Authors:  Rubin M Tuder; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-18       Impact factor: 5.464

Review 6.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

7.  Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.

Authors:  Nathane Santanna Felix; Lucas de Mendonça; Cassia Lisboa Braga; Jaqueline Soares da Silva; Cynthia Dos Santos Samary; Juliana Borges Vieira; Fernanda Cruz; Nazareth de Novaes Rocha; Gisele Zapata-Sudo; Patricia Rieken Macedo Rocco; Pedro Leme Silva
Journal:  Br J Pharmacol       Date:  2019-12-05       Impact factor: 8.739

8.  Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension.

Authors:  Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2020-09-10       Impact factor: 3.017

Review 9.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

10.  Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.

Authors:  Ahmed U Fayyaz; William D Edwards; Joseph J Maleszewski; Ewa A Konik; Hilary M DuBrock; Barry A Borlaug; Robert P Frantz; Sarah M Jenkins; Margaret M Redfield
Journal:  Circulation       Date:  2017-12-15       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.